title: Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects.
abstract: The interaction of clomipramine and moclobemide with alcohol was compared in a double blind parallel groups study in 24 healthy volunteers. Moclobemide was given at the highest recommended therapeutic dose (200 mg t.i.d.) and clomipramine in a subtherapeutic dose (25 mg b.i.d.) because of its poor tolerance in healthy subjects. Psychometric evaluations were performed during a placebo run-in phase; after a 5-day treatment period; assessments were made before, and again 1 h and 4 h after alcohol ingestion. Alcohol doses were pre-determined for each subject in order to produce a blood alcohol concentration of 0.6 g/l 1 h after alcohol intake and this individual alcohol dose was given on test days. The day before alcohol intake tests for autonomic functions were made to assess the anticholinergic effects of the drugs. Alcohol significantly increased body sway, decreased critical flicker fusion frequency, prolonged choice reaction time, impaired copying skills, impaired memory and increased the subjective feelings of satisfaction and tension. Drugs increased the effect of alcohol on body sway and this was essentially due to clomipramine. Clomipramine both without and with alcohol increased body sway, prolonged choice reaction time more than did moclobemide. Clomipramine seemed to diminish alcohol-induced memory impairment in one of the memory tests used. Subjects taking clomipramine had significantly more adverse effects after alcohol ingestion than did subjects of the moclobemide group. In contrast to moclobemide, clomipramine produced a moderate but significant drop in standing systolic blood pressure and a clear inhibition of salivary excretion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Berlin
authors.forename: A
authors.initials: A
authors.lastname: Cournot
authors.forename: R
authors.initials: R
authors.lastname: Zimmer
authors.forename: A M
authors.initials: AM
authors.lastname: Pedarriosse
authors.forename: R
authors.initials: R
authors.lastname: Manfredi
authors.forename: P
authors.initials: P
authors.lastname: Molinier
authors.forename: A J
authors.initials: AJ
authors.lastname: Puech
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D001288:Attention / Q000187:drug effects; D001341:Autonomic Nervous System / Q000187:drug effects; D001549:Benzamides / Q000009:adverse effects / Q000494:pharmacology*; D002997:Clomipramine / Q000009:adverse effects / Q000494:pharmacology*; D004347:Drug Interactions; D000431:Ethanol / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D005425:Flicker Fusion / Q000187:drug effects; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects*
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D000431:Ethanol; D002997:Clomipramine; D020912:Moclobemide